There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Transthyretin


Transthyretin Molecule Information

Target Synonym:TTR;Transthyretin;TBPA;PALB;ATTR;Prealbumin
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Transthyretin Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TTR-H5223 Human Human Transthyretin / Prealbumin Protein, His Tag

Transthyretin Molecule Synonym Name


Transthyretin Molecule Background

Transthyretin (TTR) is also known as Prealbumin, ATTR, TBPA, PALB, which belongs to the transthyretin family. Transthyretin / TTR is a serum and cerebrospinal fluid carrier of the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol. In cerebrospinal fluid TTR is the primary carrier of T4. TTR also acts as a carrier of retinol (vitamin A) through its association with retinol-binding protein (RBP) in the blood and the CSF. Less than 1% of TTR's T4 binding sites are occupied in blood. TTR misfolding and aggregation is known to be associated with the amyloid diseases.

Transthyretin References

Transthyretin Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Inotersen sodium GSK-2998728; ISIS-420915 Approved Ionis, Akcea inotersen sodium ema

Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

Akcea Therapeutics Ireland Limited 2018-07-05 Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis Details
Patisiran ALN-18328; ALN-TTR02; GENZ-438027; SAR-438037 Approved Alnylam, Sanofi ONPATTRO fda Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis ALNYLAM PHARMS INC 2018-08-10 Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis Details
Tafamidis Meglumine Fx-1006A; FX-1006A; PF-06291826; PF-6291826 Approved Pfizer tafamidis ema

Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Pfizer Europe MA EEIG 2011-11-16 Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis Details

Transthyretin Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ION-682884 AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx; IONIS-TTR-LRx Phase Ⅲ Ionis Pharmaceuticals, Akcea Transthyretin amyloidosis Details
PRX-004 PRX-004 Phase Ⅰ Prothena Transthyretin amyloidosis Details
AG-10 AG-10; BBP-265 Phase Ⅲ Stanford University, Bridge, Alexion Pharmaceuticals Transthyretin amyloidosis Details
Vutrisiran ALN-TTRSC02 Phase Ⅲ Alnylam Transthyretin amyloidosis Details
NI-006 NI-006,NI006 Phase Ⅰ Neurimmune Transthyretin-Related Amyloid Cardiomyopathy Details
Revusiran SAR-438714 Phase Ⅲ Alnylam, Sanofi Transthyretin amyloidosis, Amyloid polyneuropathy Details
ALN-TTR01 ALN-TTR01 Phase Ⅰ Alnylam Transthyretin amyloidosis Details

This web search service is supported by Google Inc.